MENU
+Compare
GLUE
Stock ticker: NASDAQ
AS OF
Sep 24, 04:59 PM (EDT)
Price
$6.63
Change
+$0.30 (+4.74%)
Capitalization
390.94M

GLUE Monte Rosa Therapeutics Forecast, Technical & Fundamental Analysis

Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins... Show more

GLUE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for GLUE with price predictions
Sep 23, 2025

GLUE's RSI Oscillator leaves overbought zone

The 10-day RSI Oscillator for GLUE moved out of overbought territory on September 19, 2025. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 instances where the indicator moved out of the overbought zone. In of the 21 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 37 cases where GLUE's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GLUE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

GLUE broke above its upper Bollinger Band on September 15, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 15, 2025. You may want to consider a long position or call options on GLUE as a result. In of 75 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for GLUE just turned positive on August 22, 2025. Looking at past instances where GLUE's MACD turned positive, the stock continued to rise in of 40 cases over the following month. The odds of a continued upward trend are .

GLUE moved above its 50-day moving average on September 15, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for GLUE crossed bullishly above the 50-day moving average on September 15, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GLUE advanced for three days, in of 248 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 113 cases where GLUE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. GLUE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.458) is normal, around the industry mean (19.924). P/E Ratio (16.231) is within average values for comparable stocks, (54.318). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.126). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (2.934) is also within normal values, averaging (347.892).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GLUE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
GLUE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

GLUE is expected to report earnings to fall 8.34% to -32 cents per share on November 06

Monte Rosa Therapeutics GLUE Stock Earnings Reports
Q3'25
Est.
$-0.33
Q2'25
Beat
by $0.02
Q1'25
Beat
by $1.01
Q4'24
Missed
by $0.54
Q3'24
Beat
by $0.18
The last earnings report on August 07 showed earnings per share of -35 cents, beating the estimate of -37 cents. With 386.12K shares outstanding, the current market capitalization sits at 390.94M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
321 Harrison Avenue
Phone
+1 617 949-2643
Employees
133
Web
https://www.monterosatx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CPCAF1.35N/A
N/A
Cathay Pacific Airways, Ltd.
HKTVY3.69N/A
N/A
Hong Kong Technology Venture Company Ltd
MNHFF72.00N/A
N/A
Mayr-Melnhof Karton AG
NVSEF121.70-2.08
-1.68%
Novartis AG
FNCJF0.07N/A
-1.81%
Fancamp Exploration Ltd.

GLUE and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, GLUE has been loosely correlated with EYPT. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if GLUE jumps, then EYPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GLUE
1D Price
Change %
GLUE100%
-3.06%
EYPT - GLUE
46%
Loosely correlated
+0.22%
ANIX - GLUE
42%
Loosely correlated
-2.01%
ITRM - GLUE
40%
Loosely correlated
+4.35%
IMNM - GLUE
39%
Loosely correlated
+8.09%
OCGN - GLUE
37%
Loosely correlated
+19.42%
More